Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-01-02

Clinical Trial Update: GSK1120212+GSK2141795 for Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of GSK1120212 + GSK2141795 for cervical cancer was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GSK1120212 (trametinib)
  • GSK2141795 (GSK2141795)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Cervical Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-01-02